Endpoints and follow-up
The primary endpoint of our study was freedom from any AF/atrial
tachycardia episode lasting more than 30 seconds after the
endo-/epicardial CA. AF/atrial tachycardia occurring within the first
three month after the procedure (also known as “blanking period”) were
not counted in the primary outcome analysis, in accordance with existing
guidelines.2 The secondary endpoint was the change in
the European Heart Rhythm Association (EHRA) score over follow-up.
Patients were followed by symptoms, ECG, and 24-hour Holter monitor
recordings one, three, six, nine, and twelve months after CA;
furthermore, arrhythmia recurrences were assessed by implantable loop
recorders or pacemakers/defibrillators with atrial leads, when
available.